Home The Word Brain	My Amedeo FAQ Privacy About
	2049 Chinese The 20K Word Road to Mandarin Proficiency By B. S. Kamps et al.

Multiple Sclerosis

Free Subscription Articles published in PLoS One Retrieve available abstracts of 112 articles: HTML format

Single Articles

January 2024
1. TOLF A, Gauffin H, Burman J, Landtblom AM, et al
   Experiences of being treated with autologous haematopoietic stem cell transplantation for aggressive multiple sclerosis: A qualitative interview study.
   PLoS One. 2024;19:e0297573.
   PubMed     Abstract available
   
   
   
2. SHEMIRANI F, Pingel WR, Titcomb TJ, Salari-Moghaddam A, et al
   The effect of dietary interventions on inflammatory biomarkers among people with multiple sclerosis: A protocol for systematic review and meta-analysis of randomized controlled trials.
   PLoS One. 2024;19:e0297510.
   PubMed     Abstract available
   
   
   
3. DADVAR A, Jameie M, Azizmohammad Looha M, Parsaei M, et al
   Potential efficacy of caffeine ingestion on balance and mobility in patients with multiple sclerosis: Preliminary evidence from a single-arm pilot clinical trial.
   PLoS One. 2024;19:e0297235.
   PubMed     Abstract available
   
   
   
4. JOZEF M, Locatelli I, Brecl Jakob G, Savsek L, et al
   Psychometric evaluation of the 5-item Medication Adherence Report Scale questionnaire in persons with multiple sclerosis.
   PLoS One. 2024;19:e0294116.
   PubMed     Abstract available
   
   
   
5. LIU Z, Fan T, Mo X, Kan J, et al
   Association between multiple sclerosis and cancer risk: A two-sample Mendelian randomization study.
   PLoS One. 2024;19:e0298271.
   PubMed     Abstract available
   
   
   
6. CARATIS F, Opielka M, Hausmann M, Velasco-Estevez M, et al
   The proton-sensing receptors TDAG8 and GPR4 are differentially expressed in human and mouse oligodendrocytes: Exploring their role in neuroinflammation and multiple sclerosis.
   PLoS One. 2024;19:e0283060.
   PubMed     Abstract available
   
   
   
7. LEREIM RR, Nytrova P, Guldbrandsen A, Havrdova EK, et al
   Natalizumab promotes anti-inflammatory and repair effects in multiple sclerosis.
   PLoS One. 2024;19:e0300914.
   PubMed     Abstract available
   
   
   
8. BRNABIC AJM, Curtis SE, Johnston JA, Lo A, et al
   Incidence of type 2 diabetes, cardiovascular disease and chronic kidney disease in patients with multiple sclerosis initiating disease-modifying therapies: Retrospective cohort study using a frequentist model averaging statistical framework.
   PLoS One. 2024;19:e0300708.
   PubMed     Abstract available
   
   
   
9. IMRAISH A, Abu Thiab T, Alsalem M, Dahbour S, et al
   The neuroprotective effect of human primary astrocytes in multiple sclerosis: In vitro model.
   PLoS One. 2024;19:e0300203.
   PubMed     Abstract available
   
   
   
10. KAMPAITE A, Gustafsson R, York EN, Foley P, et al
    Brain connectivity changes underlying depression and fatigue in relapsing-remitting multiple sclerosis: A systematic review.
    PLoS One. 2024;19:e0299634.
    PubMed     Abstract available
    
    
    January 2023
11. PRUMMER JK, Stein VM, Marti E, Lutterotti A, et al
    Assessment of oligoclonal bands in cerebrospinal fluid and serum of dogs with meningoencephalitis of unknown origin.
    PLoS One. 2023;18:e0280864.
    PubMed     Abstract available
    
    
    
12. GRANJA DOMINGUEZ A, Romero Sevilla R, Aleman A, Duran C, et al
    Study for the validation of the FeetMe(R) integrated sensor insole system compared to GAITRite(R) system to assess gait characteristics in patients with multiple sclerosis.
    PLoS One. 2023;18:e0272596.
    PubMed     Abstract available
    
    
    
13. HARARI G, Gurevich M, Dolev M, Zilkha Falb R, et al
    Faster progression to multiple sclerosis disability is linked to neuronal pathways associated with neurodegeneration: An ethnicity study.
    PLoS One. 2023;18:e0280515.
    PubMed     Abstract available
    
    
    
14. BARAK-CORREN Y, Castro VM, Javitt S, Nock MK, et al
    Improving risk prediction for target subpopulations: Predicting suicidal behaviors among multiple sclerosis patients.
    PLoS One. 2023;18:e0277483.
    PubMed     Abstract available
    
    
    
15. SOKRATOUS D, Charalambous CC, Papanicolaou EZ, Michailidou K, et al
    Investigation of in-phase bilateral exercise effects on corticospinal plasticity in relapsing remitting multiple sclerosis: A registered report single-case concurrent multiple baseline design across five subjects.
    PLoS One. 2023;18:e0272114.
    PubMed     Abstract available
    
    
    
16. ERSOY T, Hocaoglu E
    A 3-DoF robotic platform for the rehabilitation and assessment of reaction time and balance skills of MS patients.
    PLoS One. 2023;18:e0280505.
    PubMed     Abstract available
    
    
    
17. SEDIGHI B, Haghdoost A, Jangipour Afshar P, Abna Z, et al
    Multiple sclerosis and COVID-19: A retrospective study in Iran.
    PLoS One. 2023;18:e0283538.
    PubMed     Abstract available
    
    
    
18. LAICHINGER K, Bombach P, Dunschede J, Ruschil C, et al
    No evidence of oligoclonal bands, intrathecal immunoglobulin synthesis and B cell recruitment in acute ischemic stroke.
    PLoS One. 2023;18:e0283476.
    PubMed     Abstract available
    
    
    
19. ZAFEIRI L, Akerfeldt T, Tolf A, Carlson K, et al
    Anti-Mullerian hormone and pregnancy after autologous hematopoietic stem cell transplantation for multiple sclerosis.
    PLoS One. 2023;18:e0284288.
    PubMed     Abstract available
    
    
    
20. BENINI S, Pellegrini E, Descovich C, Lugaresi A, et al
    Burden and resources in caregivers of people with multiple sclerosis: A qualitative study.
    PLoS One. 2023;18:e0265297.
    PubMed     Abstract available
    
    
    
21. STAHL D, Friberg E
    Formal help for persons with multiple sclerosis-Background factors associated with usage of personal assistance and home help in Sweden.
    PLoS One. 2023;18:e0286010.
    PubMed     Abstract available
    
    
    
22. EVEREST E, Uygunoglu U, Tutuncu M, Bulbul A, et al
    Prospective outcome analysis of multiple sclerosis cases reveals candidate prognostic cerebrospinal fluid markers.
    PLoS One. 2023;18:e0287463.
    PubMed     Abstract available
    
    
    
23. GOODIN DS, Khankhanian P, Gourraud PA, Vince N, et al
    Multiple sclerosis: Exploring the limits and implications of genetic and environmental susceptibility.
    PLoS One. 2023;18:e0285599.
    PubMed     Abstract available
    
    
    
24. ESCHWEILER M, McCrum C, Giannouli E
    A registered report of a crossover study on the effects of face masks on walking adaptability in people with Parkinson's disease and multiple sclerosis.
    PLoS One. 2023;18:e0286402.
    PubMed     Abstract available
    
    
    
25. VILADES E, Cordon B, Perez-Velilla J, Orduna E, et al
    Evaluation of multiple sclerosis severity using a new OCT tool.
    PLoS One. 2023;18:e0288581.
    PubMed     Abstract available
    
    
    
26. NAISBY J, Wilson-Menzfeld G, Baker K, Morris R, et al
    Yoga and Multiple Sclerosis: Maintaining engagement in physical activity.
    PLoS One. 2023;18:e0288319.
    PubMed     Abstract available
    
    
    
27. FRAGKIADAKI E, Cotterill N, Rice C, Smith JA, et al
    Evaluation of the feasibility and acceptability of an integrative group psychological intervention for people with Multiple Sclerosis: A study protocol.
    PLoS One. 2023;18:e0288295.
    PubMed     Abstract available
    
    
    
28. RAZIA R, Majeed F, Amin R, Mukhtar S, et al
    Predictive value of alpha-synuclein expression in peripheral blood of multiple sclerosis patients: A two-dimensional assessment of a selected biomarker.
    PLoS One. 2023;18:e0285022.
    PubMed     Abstract available
    
    
    
29. MACHADO A, Azad A, Pettersson E, Hillert J, et al
    Gender differences in earnings among people with multiple sclerosis and associations with type of occupation and family composition: A population-based study with matched references.
    PLoS One. 2023;18:e0288998.
    PubMed     Abstract available
    
    
    
30. MEIJBOOM R, York EN, Kampaite A, Harris MA, et al
    Patterns of brain atrophy in recently-diagnosed relapsing-remitting multiple sclerosis.
    PLoS One. 2023;18:e0288967.
    PubMed     Abstract available
    
    
    
31. HERNANDEZ M, Ramon-Julvez U, Vilades E, Cordon B, et al
    Explainable artificial intelligence toward usable and trustworthy computer-aided diagnosis of multiple sclerosis from Optical Coherence Tomography.
    PLoS One. 2023;18:e0289495.
    PubMed     Abstract available
    
    
    
32. HARRIS VK, Wollowitz J, Greenwald J, Carlson AL, et al
    Mesenchymal stem cell-neural progenitors are enriched in cell signaling molecules implicated in their therapeutic effect in multiple sclerosis.
    PLoS One. 2023;18:e0290069.
    PubMed     Abstract available
    
    
    
33. POLICK CS, Ploutz-Snyder R, Braley TJ, Connell CM, et al
    Fatigue, pain interference, and psychiatric morbidity in multiple sclerosis: The role of childhood stress.
    PLoS One. 2023;18:e0292233.
    PubMed     Abstract available
    
    
    
34. WOCHATZ M, Schraplau A, Engel T, Zecher MM, et al
    Correction: Application of eccentric training in various clinical populations: Protocol for a multi-centered pilot and feasibility study in people with low back pain and people with multiple sclerosis.
    PLoS One. 2023;18:e0293225.
    PubMed     Abstract available
    
    
    
35. O'MALLEY N, Coote S, Staunton FM, O'Connor E, et al
    A core outcome set for evaluating the effectiveness of mixed-diagnosis falls prevention interventions for people with Multiple Sclerosis, Parkinson's Disease and stroke.
    PLoS One. 2023;18:e0294193.
    PubMed     Abstract available
    
    
    
36. KRAKENES T, Wergeland S, Al-Sharabi N, Mohamed-Ahmed S, et al
    The neuroprotective potential of mesenchymal stem cells from bone marrow and human exfoliated deciduous teeth in a murine model of demyelination.
    PLoS One. 2023;18:e0293908.
    PubMed     Abstract available
    
    
    
37. WILF-YARKONI A, Feldmann K, Rubarth K, Dorsch EM, et al
    Effectiveness of oral prednisone tapering following intravenous methylprednisolone for acute optic neuritis in multiple sclerosis.
    PLoS One. 2023;18:e0288366.
    PubMed     Abstract available
    
    
    January 2022
38. HORTON MK, McCurdy S, Shao X, Bellesis K, et al
    Case-control study of adverse childhood experiences and multiple sclerosis risk and clinical outcomes.
    PLoS One. 2022;17:e0262093.
    PubMed     Abstract available
    
    
    
39. SARPONG-KUMANKOMAH S, Knox KB, Kelly ME, Hunter G, et al
    Quantification of human plasma metalloproteins in multiple sclerosis, ischemic stroke and healthy controls reveals an association of haptoglobin-hemoglobin complexes with age.
    PLoS One. 2022;17:e0262160.
    PubMed     Abstract available
    
    
    
40. WIJEYARATNAM DO, Edwards T, Pilutti LA, Cressman EK, et al
    Assessing visually guided reaching in people with multiple sclerosis with and without self-reported upper limb impairment.
    PLoS One. 2022;17:e0262480.
    PubMed     Abstract available
    
    
    
41. AL-KAFAJI G, Bakheit HF, AlAli F, Fattah M, et al
    Next-generation sequencing of the whole mitochondrial genome identifies functionally deleterious mutations in patients with multiple sclerosis.
    PLoS One. 2022;17:e0263606.
    PubMed     Abstract available
    
    
    
42. CHOI S, Spini M, Hua J, Harrison DM, et al
    Correction: Blood-brain barrier breakdown in non-enhancing multiple sclerosis lesions detected by 7-Tesla MP2RAGE DeltaT1 mapping.
    PLoS One. 2022;17:e0264452.
    PubMed     Abstract available
    
    
    
43. KOKAS Z, Sandi D, Fricska-Nagy Z, Fuvesi J, et al
    Do Hungarian multiple sclerosis care units fulfil international criteria?
    PLoS One. 2022;17:e0264328.
    PubMed     Abstract available
    
    
    
44. SHOBEIRI P, Karimi A, Momtazmanesh S, Teixeira AL, et al
    Exercise-induced increase in blood-based brain-derived neurotrophic factor (BDNF) in people with multiple sclerosis: A systematic review and meta-analysis of exercise intervention trials.
    PLoS One. 2022;17:e0264557.
    PubMed     Abstract available
    
    
    
45. CORTESI PA, Antonazzo IC, Gasperini C, Nica M, et al
    Cost-effectiveness and budget impact analysis of siponimod in the treatment of secondary progressive multiple sclerosis in Italy.
    PLoS One. 2022;17:e0264123.
    PubMed     Abstract available
    
    
    
46. MIKKELSEN AP, Egerup P, Kolte AM, Westergaard D, et al
    Pregnancy loss and risk of multiple sclerosis and autoimmune neurological disorder: A nationwide cohort study.
    PLoS One. 2022;17:e0266203.
    PubMed     Abstract available
    
    
    
47. MIRMOSAYYEB O, Ebrahimi N, Barzegar M, Afshari-Safavi A, et al
    Olfactory dysfunction in patients with multiple sclerosis; A systematic review and meta-analysis.
    PLoS One. 2022;17:e0266492.
    PubMed     Abstract available
    
    
    
48. ROMERO-PINEL L, Bau L, Matas E, Leon I, et al
    Cost associated with a relapse-free patient in multiple sclerosis: A real-world health indicator.
    PLoS One. 2022;17:e0267504.
    PubMed     Abstract available
    
    
    
49. WILSON-MENZFELD G, Naisby J, Baker K, Morris R, et al
    Yoga provision for individuals living with Multiple Sclerosis: Is the future online?
    PLoS One. 2022;17:e0266786.
    PubMed     Abstract available
    
    
    
50. YADAV M, Ali S, Shrode RL, Shahi SK, et al
    Multiple sclerosis patients have an altered gut mycobiome and increased fungal to bacterial richness.
    PLoS One. 2022;17:e0264556.
    PubMed     Abstract available
    
    
    
51. BIERNACKI T, Sandi D, Fuvesi J, Fricska-Nagy Z, et al
    The safety and efficacy of fingolimod: Real-world data from a long-term, non-interventional study on the treatment of RRMS patients spanning up to 5 years from Hungary.
    PLoS One. 2022;17:e0267346.
    PubMed     Abstract available
    
    
    
52. GIOVANNETTI AM, Pakenham KI, Presti G, Quartuccio ME, et al
    A group resilience training program for people with multiple sclerosis: Study protocol of a multi-centre cluster-randomized controlled trial (multi-READY for MS).
    PLoS One. 2022;17:e0267245.
    PubMed     Abstract available
    
    
    
53. BOIS A, Tervil B, Moreau A, Vienne-Jumeau A, et al
    A topological data analysis-based method for gait signals with an application to the study of multiple sclerosis.
    PLoS One. 2022;17:e0268475.
    PubMed     Abstract available
    
    
    
54. ALVAREZ-RODRIGUEZ E, Sanchez-Franco CM, Perez-Haro MJ, Bello-Otero L, et al
    Development of a scale for the evaluation of the quality of the shared decision process in multiple sclerosis patients.
    PLoS One. 2022;17:e0268125.
    PubMed     Abstract available
    
    
    
55. KOFFMAN J, Penfold C, Cottrell L, Farsides B, et al
    "I wanna live and not think about the future" what place for advance care planning for people living with severe multiple sclerosis and their families? A qualitative study.
    PLoS One. 2022;17:e0265861.
    PubMed     Abstract available
    
    
    
56. ELKHALII-WILHELM S, Sippel A, Riemann-Lorenz K, Kofahl C, et al
    Experiences of persons with Multiple Sclerosis with lifestyle adjustment-A qualitative interview study.
    PLoS One. 2022;17:e0268988.
    PubMed     Abstract available
    
    
    
57. RASKIN E, Achiron A, Zloto O, Neuman R, et al
    Uveitis prior to clinical presentation of Multiple Sclerosis (MS) is associated with better MS prognosis.
    PLoS One. 2022;17:e0264918.
    PubMed     Abstract available
    
    
    
58. PETRZALKA M, Meluzinova E, Libertinova J, Mojzisova H, et al
    IL-2, IL-6 and chitinase 3-like 2 might predict early relapse activity in multiple sclerosis.
    PLoS One. 2022;17:e0270607.
    PubMed     Abstract available
    
    
    
59. KRAUSE A, Lee K, Konig D, Faist M, et al
    Six weeks of whole-body vibration improves fine motor accuracy, functional mobility and quality of life in people with multiple sclerosis.
    PLoS One. 2022;17:e0270698.
    PubMed     Abstract available
    
    
    
60. ZANOTTO T, Rice LA, Sosnoff JJ
    Frailty among people with multiple sclerosis who are wheelchair users.
    PLoS One. 2022;17:e0271688.
    PubMed     Abstract available
    
    
    
61. VITTURI BK, Rahmani A, Dini G, Montecucco A, et al
    Spatial and temporal distribution of the prevalence of unemployment and early retirement in people with multiple sclerosis: A systematic review with meta-analysis.
    PLoS One. 2022;17:e0272156.
    PubMed     Abstract available
    
    
    
62. TU H, Li N, Liu W, Fan Z, et al
    Effects of transcutaneous tibial nerve stimulation on females with overactive bladder syndrome in multiple sclerosis a protocol for a systematic review and meta-analysis.
    PLoS One. 2022;17:e0269371.
    PubMed     Abstract available
    
    
    
63. ABUAF AF, Bunting SR, Klein S, Carroll T, et al
    Analysis of the extent of limbic system changes in multiple sclerosis using FreeSurfer and voxel-based morphometry approaches.
    PLoS One. 2022;17:e0274778.
    PubMed     Abstract available
    
    
    
64. KUENDIG S, Kool J, Polhemus A, Schallert W, et al
    Three weeks of rehabilitation improves walking capacity but not daily physical activity in patients with multiple sclerosis with moderate to severe walking disability.
    PLoS One. 2022;17:e0274348.
    PubMed     Abstract available
    
    
    
65. NING L, Wang B
    Neurofilament light chain in blood as a diagnostic and predictive biomarker for multiple sclerosis: A systematic review and meta-analysis.
    PLoS One. 2022;17:e0274565.
    PubMed     Abstract available
    
    
    
66. YANG B, Parker RB, Meibohm B, Temrikar ZH, et al
    Alcohol inhibits the metabolism of dimethyl fumarate to the active metabolite responsible for decreasing relapse frequency in the treatment of multiple sclerosis.
    PLoS One. 2022;17:e0278111.
    PubMed     Abstract available
    
    
    
67. VALORI M, Lehikoinen J, Jansson L, Clancy J, et al
    High prevalence of low-allele-fraction somatic mutations in STAT3 in peripheral blood CD8+ cells in multiple sclerosis patients and controls.
    PLoS One. 2022;17:e0278245.
    PubMed     Abstract available
    
    
    
68. CLARKSON TC, Iguchi N, Xie AX, Malykhina AP, et al
    Differential transcriptomic changes in the central nervous system and urinary bladders of mice infected with a coronavirus.
    PLoS One. 2022;17:e0278918.
    PubMed     Abstract available
    
    
    
69. AL-KAFAJI G, Alwehaidah MS, Alsabbagh MM, Alharbi MA, et al
    Mitochondrial DNA haplogroup analysis in Saudi Arab patients with multiple sclerosis.
    PLoS One. 2022;17:e0279237.
    PubMed     Abstract available
    
    
    
70. WOCHATZ M, Schraplau A, Engel T, Zecher MM, et al
    Application of eccentric training in various clinical populations: Protocol for a multi-centered pilot and feasibility study in people with low back pain and people with multiple sclerosis.
    PLoS One. 2022;17:e0270875.
    PubMed     Abstract available
    
    
    
71. BEECHAM AH, Amezcua L, Chinea A, Manrique CP, et al
    Ancestral risk modification for multiple sclerosis susceptibility detected across the Major Histocompatibility Complex in a multi-ethnic population.
    PLoS One. 2022;17:e0279132.
    PubMed     Abstract available
    
    
    January 2021
72. JOHNSON DK, Reynolds KM, Poole BD, Montierth MD, et al
    Contribution of viral infection to risk for cancer in systemic lupus erythematosus and multiple sclerosis.
    PLoS One. 2021;16:e0243150.
    PubMed     Abstract available
    
    
    
73. THALER C, Kyselyova AA, Faizy TD, Nawka MT, et al
    Heterogeneity of multiple sclerosis lesions in fast diffusional kurtosis imaging.
    PLoS One. 2021;16:e0245844.
    PubMed     Abstract available
    
    
    
74. WILSKI M, Brola W, Luniewska M, Tomczak M, et al
    The perceived impact of multiple sclerosis and self-management: The mediating role of coping strategies.
    PLoS One. 2021;16:e0248135.
    PubMed     Abstract available
    
    
    
75. GOODIN DS, Khankhanian P, Gourraud PA, Vince N, et al
    The nature of genetic and environmental susceptibility to multiple sclerosis.
    PLoS One. 2021;16:e0246157.
    PubMed     Abstract available
    
    
    
76. PRIDHAM G, Hossain S, Rawji KS, Zhang Y, et al
    A metric learning method for estimating myelin content based on T2-weighted MRI from a de- and re-myelination model of multiple sclerosis.
    PLoS One. 2021;16:e0249460.
    PubMed     Abstract available
    
    
    
77. GOUJON A, Mirafzal S, Zuber K, Deschamps R, et al
    3D-Fast Gray Matter Acquisition with Phase Sensitive Inversion Recovery Magnetic Resonance Imaging at 3 Tesla: Application for detection of spinal cord lesions in patients with multiple sclerosis.
    PLoS One. 2021;16:e0247813.
    PubMed     Abstract available
    
    
    
78. CHOI S, Spini M, Hua J, Harrison DM, et al
    Blood-brain barrier breakdown in non-enhancing multiple sclerosis lesions detected by 7-Tesla MP2RAGE DeltaT1 mapping.
    PLoS One. 2021;16:e0249973.
    PubMed     Abstract available
    
    
    
79. GOLAN D, Sagiv S, Glass-Marmor L, Miller A, et al
    Mobile-phone-based e-diary derived patient reported outcomes: Association with clinical disease activity, psychological status and quality of life of patients with multiple sclerosis.
    PLoS One. 2021;16:e0250647.
    PubMed     Abstract available
    
    
    
80. KLISTORNER S, Barnett MH, Wasserthal J, Yiannikas C, et al
    Differentiating axonal loss and demyelination in chronic MS lesions: A novel approach using single streamline diffusivity analysis.
    PLoS One. 2021;16:e0244766.
    PubMed     Abstract available
    
    
    
81. PAPP V, Buron MD, Siersma V, Rasmussen PV, et al
    Real-world outcomes for a complete nationwide cohort of more than 3200 teriflunomide-treated multiple sclerosis patients in The Danish Multiple Sclerosis Registry.
    PLoS One. 2021;16:e0250820.
    PubMed     Abstract available
    
    
    
82. KOENIG KA, Beall EB, Sakaie KE, Ontaneda D, et al
    Evaluation of a connectivity-based imaging metric that reflects functional decline in Multiple Sclerosis.
    PLoS One. 2021;16:e0251338.
    PubMed     Abstract available
    
    
    
83. CARTER B, Hayes C, Smith A, Pennington A, et al
    A single patient reported outcome measure for acquired brain injury, multiple sclerosis & Parkinson's disease.
    PLoS One. 2021;16:e0251484.
    PubMed     Abstract available
    
    
    
84. ROGACZEWSKA M, Michalak S, Stopa M
    Macular vessel density differs in multiple sclerosis and neuromyelitis optica spectrum disorder: An optical coherence tomography angiography study.
    PLoS One. 2021;16:e0253417.
    PubMed     Abstract available
    
    
    
85. BSTEH G, Assar H, Hegen H, Heschl B, et al
    COVID-19 severity and mortality in multiple sclerosis are not associated with immunotherapy: Insights from a nation-wide Austrian registry.
    PLoS One. 2021;16:e0255316.
    PubMed     Abstract available
    
    
    
86. GOODIN DS, Oksenberg JR, Douillard V, Gourraud PA, et al
    Genetic susceptibility to multiple sclerosis in African Americans.
    PLoS One. 2021;16:e0254945.
    PubMed     Abstract available
    
    
    
87. SERAJI M, Mohebbi M, Safari A, Krekelberg B, et al
    Multiple sclerosis reduces synchrony of the magnocellular pathway.
    PLoS One. 2021;16:e0255324.
    PubMed     Abstract available
    
    
    
88. GAJ S, Ontaneda D, Nakamura K
    Automatic segmentation of gadolinium-enhancing lesions in multiple sclerosis using deep learning from clinical MRI.
    PLoS One. 2021;16:e0255939.
    PubMed     Abstract available
    
    
    
89. NG KEE KWONG KC, Mollison D, Meijboom R, York EN, et al
    The prevalence of paramagnetic rim lesions in multiple sclerosis: A systematic review and meta-analysis.
    PLoS One. 2021;16:e0256845.
    PubMed     Abstract available
    
    
    
90. SANTISTEBAN L, Teremetz M, Irazusta J, Lindberg PG, et al
    Outcome measures used in trials on gait rehabilitation in multiple sclerosis: A systematic literature review.
    PLoS One. 2021;16:e0257809.
    PubMed     Abstract available
    
    
    
91. MOCCIA M, Affinito G, Capacchione A, Lanzillo R, et al
    Interferon beta for the treatment of multiple sclerosis in the Campania Region of Italy: Merging the real-life to routinely collected healthcare data.
    PLoS One. 2021;16:e0258017.
    PubMed     Abstract available
    
    
    
92. MECA-LALLANA JE, Oreja-Guevara C, Munoz D, Olascoaga J, et al
    Four-year safety and effectiveness data from patients with multiple sclerosis treated with fingolimod: The Spanish GILENYA registry.
    PLoS One. 2021;16:e0258437.
    PubMed     Abstract available
    
    
    
93. STERNBACH S, West N, Singhal NK, Clements R, et al
    The BHMT-betaine methylation pathway epigenetically modulates oligodendrocyte maturation.
    PLoS One. 2021;16:e0250486.
    PubMed     Abstract available
    
    
    
94. ROZYCKA J
    How I see is how I feel. Identification of illness perception schema and its association with adaptation outcomes in multiple sclerosis - a 5-year prospective study.
    PLoS One. 2021;16:e0258740.
    PubMed     Abstract available
    
    
    
95. ALKETBI A, Basit S, Hamza N, Walton LM, et al
    The added value of cognition-targeted exercise versus symptom-targeted exercise for multiple sclerosis fatigue: A randomized controlled pilot trial.
    PLoS One. 2021;16:e0258752.
    PubMed     Abstract available
    
    
    
96. KRUGER K, Fricke LM, Dilger EM, Thiele A, et al
    How is and how should healthcare for people with multiple sclerosis in Germany be designed?-The rationale and protocol for the mixed-methods study Multiple Sclerosis-Patient-Oriented Care in Lower Saxony (MS-PoV).
    PLoS One. 2021;16:e0259855.
    PubMed     Abstract available
    
    
    
97. VERES G, Vas NF, Lyngby Lassen M, Beresova M, et al
    Effect of grey-level discretization on texture feature on different weighted MRI images of diverse disease groups.
    PLoS One. 2021;16:e0253419.
    PubMed     Abstract available
    
    
    
98. MARRIE RA, Walld R, Bolton JM, Sareen J, et al
    Effect of comorbid mood and anxiety disorders on breast and cervical cancer screening in immune-mediated inflammatory disease.
    PLoS One. 2021;16:e0249809.
    PubMed     Abstract available
    
    
    
99. MIMPEN M, Rolf L, Poelmans G, van den Ouweland J, et al
    Vitamin D related genetic polymorphisms affect serological response to high-dose vitamin D supplementation in multiple sclerosis.
    PLoS One. 2021;16:e0261097.
    PubMed     Abstract available
    
    
    
100. ZANGENEH Z, Abdi-Ali A, Khamooshian K, Alvandi A, et al
     Bacterial variation in the oral microbiota in multiple sclerosis patients.
     PLoS One. 2021;16:e0260384.
     PubMed     Abstract available
     
     
     
101. SAPOSNIK G, Del Rio B, Bueno-Gil G, Sempere AP, et al
     Behavioral aspects of nurse practitioners associated with optimal multiple sclerosis care in Spain.
     PLoS One. 2021;16:e0261050.
     PubMed     Abstract available
     
     
     
102. VALORI M, Jansson L, Tienari PJ
     CD8+ cell somatic mutations in multiple sclerosis patients and controls-Enrichment of mutations in STAT3 and other genes implicated in hematological malignancies.
     PLoS One. 2021;16:e0261002.
     PubMed     Abstract available
     
     
     
103. AHMAD I, Wergeland S, Oveland E, Bo L, et al
     A higher proportion of ermin-immunopositive oligodendrocytes in areas of remyelination.
     PLoS One. 2021;16:e0256155.
     PubMed     Abstract available
     
     
     January 2020
104. ALNAJASHI H, Jabbad R
     Behavioral practices of patients with multiple sclerosis during Covid-19 pandemic.
     PLoS One. 2020;15:e0241103.
     PubMed     Abstract available
     
     
     
105. COTTRELL L, Economos G, Evans C, Silber E, et al
     A realist review of advance care planning for people with multiple sclerosis and their families.
     PLoS One. 2020;15:e0240815.
     PubMed     Abstract available
     
     
     
106. MELNIKOV M, Sharanova S, Sviridova A, Rogovskii V, et al
     The influence of glatiramer acetate on Th17-immune response in multiple sclerosis.
     PLoS One. 2020;15:e0240305.
     PubMed     Abstract available
     
     
     
107. PERLEJEWSKI K, Bukowska-Osko I, Rydzanicz M, Dzieciatkowski T, et al
     Search for viral agents in cerebrospinal fluid in patients with multiple sclerosis using real-time PCR and metagenomics.
     PLoS One. 2020;15:e0240601.
     PubMed     Abstract available
     
     
     
108. ZHANG X, Gao B, Xu B
     No association between the vitamin D-binding protein (DBP) gene polymorphisms (rs7041 and rs4588) and multiple sclerosis and type 1 diabetes mellitus: A meta-analysis.
     PLoS One. 2020;15:e0242256.
     PubMed     Abstract available
     
     
     
109. BEREK K, Hegen H, Auer M, Zinganell A, et al
     Cerebrospinal fluid oligoclonal bands in Neuroborreliosis are specific for Borrelia burgdorferi.
     PLoS One. 2020;15:e0239453.
     PubMed     Abstract available
     
     
     
110. NIKOLIC B, Ivancevic N, Zaletel I, Rovcanin B, et al
     Characteristics of pediatric multiple sclerosis: A tertiary referral center study.
     PLoS One. 2020;15:e0243031.
     PubMed     Abstract available
     
     
     
111. CORDON B, Vilades E, Orduna E, Satue M, et al
     Angiography with optical coherence tomography as a biomarker in multiple sclerosis.
     PLoS One. 2020;15:e0243236.
     PubMed     Abstract available
     
     
     
112. VICKARYOUS N, Jitlal M, Jacobs BM, Middleton R, et al
     Remote testing of vitamin D levels across the UK MS population-A case control study.
     PLoS One. 2020;15:e0241459.
     PubMed     Abstract available
     
     

Thank you for your interest in scientific medicine.

AMEDEO Multiple Sclerosis is free of charge.